欢迎来到PharmAsia News， 通过以下简单的注册程序，您能得到一份免费赠送的独家产业报道和同样免费定期全球医药最新信息提醒。

Thank you for your interest in the free report from PharmAsia News, the leading regulatory and business publication for biopharma executives doing business in China, India, Japan and the Pacific Rim. In this report, PharmAsia News provides an inside look at evolving R&D models in China. To receive instant access to the report, please fill out the form below.

If you do business in China, Japan, India, Korea or Australia, if you need to understand how China's SFDA or Japan's PDMA regulates the biopharma and medical device industries – from clinical trials to approvals to enforcement actions – if you partner with multinational companies operating in Asia, then you need to read what your global peers read each and every day – PharmAsia News. Register for a FREE 30 day trial.

Find out why PharmAsia News is read by U.S. FDA, and by executives at all the major multinational companies, including Pfizer, J&J, Novartis, BMS, Sanofi-Aventis and Roche — register for a FREE 30 day trial today!